Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
152
resultados
Última actualización
12/05/2025 [06:56:00]
Resultados 125 a 150 de 152
Resumen de: US2025090103A1
Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.
Resumen de: AU2025201387A1
A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
Resumen de: US2025095862A1
In some examples, an apparatus, such as a mobile phone can include an input module such as a touch screen, a camera, a processor, and computer readable medium. The camera captures one or more images of a person. The processor can use a single machine learning model to estimate the human body features of the person based on the captured images, and use the human body features to generate a disease risk assessment value associated with diabetes and cardiovascular disease risks. The human body features can include at least one or more of: 3D body shape, or body shape indicators; and one or more of: blood flow, blood pressure, heart rate, respiratory rate, heart rate variability, cardiac workload, irregular heartbeats, or stress index. The machine learning model can be trained over a set of training images.
Resumen de: US2025095869A1
Presented herein is a handheld analyte measurement device. The analyte measurement device includes one or more software applications to help the user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with the handheld analyte measurement device.
Resumen de: US2025094109A1
A continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays is disclosed, as well as systems and methods for limiting the number of display devices that can connect to a continuous glucose transmitter. In addition, security, including hashing techniques and a changing application key, can be used to provide secure communications between the continuous glucose transmitter and the displays. Also provided is a continuous glucose monitor and techniques for authenticating multiple displays, providing secure data transmissions to multiple displays, and coordinating the interaction of commands and data updates between multiple displays.
Resumen de: US2025090758A1
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.
Resumen de: US2025090753A1
Disclosed herein are techniques related to making trend based adjustments to insulin dosage. In some embodiments, the techniques may involve obtaining, based on glucose measurements performed on a person, a glucose value and a glucose rate of change (ROC). An initial insulin amount to deliver to the person is calculated based on this glucose value. However, an adjustment value can be obtained in response to a determination that the glucose value exceeds a glucose threshold, and that the glucose ROC exceeds an ROC threshold. The adjustment value represents an adjustment to be applied to the initial insulin amount when the glucose threshold and the ROC threshold are both exceeded. The adjustment value can be predetermined, based on earlier glucose measurements performed on the person. For instance, the adjustment value and the thresholds can be jointly determined through a computer simulation using a person-specific physiological model.
Resumen de: US2025090754A1
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
Resumen de: US2025090082A1
There is a need for more effective and efficient predictive data analysis, such as more effective and efficient data analysis solutions for performing predictive monitoring of the glucose-insulin endocrine metabolic regulatory system.
Resumen de: US2025090052A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: WO2025055546A1
The present application provides a tympanic membrane temperature measuring apparatus, a blood glucose measuring method, a system, and a device. First, a target tympanic membrane temperature is acquired; a target oral cavity temperature is estimated on the basis of a pre-established temperature correspondence between the tympanic membrane and the oral cavity; a temperature correspondence between blood glucose increments and oral cavity temperature increments is then established on the basis of a pre-calibrated invasive blood glucose value and an oral cavity calibration temperature, so as to calculate a target blood glucose increment; and finally, a target blood glucose value is calculated on the basis of the target blood glucose increment and the pre-calibrated invasive blood glucose value. In this way, impact of other factors on blood glucose measurement is reduced while increasing the apparent temperature in the blood glucose measurement process.
Resumen de: US2025090053A1
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation occurs in a stabilized state, thereby allowing more accurate blood glucose monitoring.
Resumen de: WO2025055545A1
The present application provides an eardrum temperature measuring apparatus, a blood sugar measuring method, a system, and a device. By means of a high-precision eardrum temperature measuring apparatus measuring multiple temperature points disposed in the ear canal, a target eardrum temperature is estimated without contacting the eardrum; next, based on the target eardrum temperature, a target oral temperature is estimated on the basis of a pre-established correspondence relationship between eardrum and oral cavity temperatures; then, by means of a pre-calibrated invasive blood sugar value and an oral calibration temperature, a temperature correspondence relationship between a blood sugar increment and an oral temperature increment is established, and a target blood sugar increment can be calculated; finally, based on the target blood sugar increment and the pre-calibrated invasive blood sugar value, a target blood sugar value is calculated, that is, by means of the precision measuring apparatus and the conversion relationships between multiple pieces of precision data, the accuracy and stability of blood sugar measurement are improved, the influence of external factors on blood sugar measurement is reduced, and the ability of a measurement process to resist interference is improved.
Resumen de: WO2025055788A1
An OCTA-based non-invasive continuous blood glucose measurement method and apparatus. The OCTA-based non-invasive continuous blood glucose measurement method comprises: performing continuous OCT scanning imaging on a target tissue region, then using a depth attenuation characteristic of an OCT signal to extract a three-dimensional scattering coefficient of the target tissue region, and generating a three-dimensional microvascular distribution of the target tissue region; then accurately distinguishing a blood scattering coefficient and a tissue scattering coefficient on the basis of the three-dimensional scattering coefficient and the three-dimensional microvascular distribution; using an electrochemical method to measure reference blood glucose concentrations at two moments, and finally, respectively combining the reference blood glucose concentrations with the blood scattering coefficient and the tissue scattering coefficient to achieve continuous measurement of a blood glucose concentration and an interstitial fluid glucose concentration. According to the method, on the basis of OCTA guidance, the synchronous measurement of the interstitial fluid glucose concentration is implemented while accurate measurement of the blood glucose concentration is implemented, and the method has a great heuristic significance for the optical non-invasive blood glucose measurement.
Resumen de: EP4523621A2
A method for providing blood glucose data is provided. In response to a suspension of a continuous basal insulin delivery, by an insulin delivery pump, the method identifies a condition indicating continuing hypoglycemia that continues when basal insulin delivery is suspended; and performs an action, by the insulin delivery pump, based on identifying the condition.
Resumen de: US12251242B1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: US2019216405A1
The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors. The method comprises steps of: receiving a glucose monitoring value by the data processing device, the glucose monitoring value indicating a glucose level sampled from a person in a bodily fluid in a glucose level measurement; receiving, by the data processing device, insulin bolus administration data indicating an insulin bolus of an insulin bolus administration; determining, by the data processing device, from an analysis of the glucose monitoring value, a carbohydrate intake event if one of the following is detected: the glucose monitoring value indicates a glucose level below a first threshold glucose level; and the glucose monitoring value indicates an elevated glucose level above a second threshold glucose level, and the insulin bolus indicated by the insulin bolus administration data is exceeding a corrective insulin bolus suitable for compensating for the elevated glucose level; and generating, by the data processing device, carbohydrate intake event data indicating the determined carbohydrate intake event. Further, a non-transitory computer readable medium is provided.
Resumen de: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Resumen de: US2019216405A1
The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors. The method comprises steps of: receiving a glucose monitoring value by the data processing device, the glucose monitoring value indicating a glucose level sampled from a person in a bodily fluid in a glucose level measurement; receiving, by the data processing device, insulin bolus administration data indicating an insulin bolus of an insulin bolus administration; determining, by the data processing device, from an analysis of the glucose monitoring value, a carbohydrate intake event if one of the following is detected: the glucose monitoring value indicates a glucose level below a first threshold glucose level; and the glucose monitoring value indicates an elevated glucose level above a second threshold glucose level, and the insulin bolus indicated by the insulin bolus administration data is exceeding a corrective insulin bolus suitable for compensating for the elevated glucose level; and generating, by the data processing device, carbohydrate intake event data indicating the determined carbohydrate intake event. Further, a non-transitory computer readable medium is provided.
Resumen de: WO2025054131A1
A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.
Resumen de: US2025082849A1
In an aspect, an apparatus for generating a temporal element of a medication is presented. The apparatus includes a display device and a processor in electronic communication with the display device. The apparatus includes a memory communicatively connected to the processor. The memory includes instructions configuring the processor to generate a user interface through the display device and receive user input from a user through the user interface. The processor is configured to receive biological data from a user through a biological sensor in communication with the processor. The biological data includes a gastric metric. The processor is configured to calculate a temporal element of a delivery of an amount of medication to the user based on the biological data and the user input. The processor is configured to communicate the temporal element of the delivery of the amount of medication to a wearable medication delivery device.
Resumen de: US2025087350A1
Provided are computer-implemented methods, systems and devices for generating a type-II (T2DM) diabetic status prediction, including: extracting voice biomarker feature values from the voice sample for predetermined voice biomarker features; determining the T2DM diabetic status prediction for the subject based on the biomarker feature values and the diabetic status prediction model; and outputting the T2DM diabetic status prediction for the subject.Provided are computer-implemented methods, systems and devices for generating a diabetic status model for predicting a T2DM diabetic status, including: diabetic status labels identifying a corresponding diabetic status for training subjects; and voice samples collected from the training subjects at different time points, each of the voice samples associated with a corresponding diabetic status label; determining voice feature values for corresponding voice features for each of the voice samples in the voice samples; and generating the diabetic status model based on the voice samples and the voice feature values.
Resumen de: US2025087348A1
A method of treatment of a type 2 diabetic patient includes selecting a type 2 diabetic patient having a predetermined comorbidity for treatment, initiating a continuous glucose monitor regimen for the selected type 2 diabetic patient, wherein after six months of initiation of the continuous glucose monitor regimen, a rate of hospitalization for a predetermined diagnostic category of the selected patient having the predetermined comorbidity is reduced by at least 12% relative to an average rate of hospitalization for the predetermined diagnostic category of selected patients having the predetermined comorbidity without the continuous glucose monitor regimen.
Resumen de: US2025085219A1
A process and sensor system with particular control of polarization of the interrogating light beams useful for determining a concentration of a targeted molecule M (such as glucose) within a given time period in a liquid sampling matrix through use of a Direct Infrared Laser Absorption Spectroscopy Technique.
Nº publicación: AU2024213143A1 13/03/2025
Solicitante:
I SENS INC
i-SENS, Inc
Resumen de: AU2024213143A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity. Current Calibration point in time value S1:25 S1:5 Ss:20 Ss :20 ->S2 :20 ->S2 :20/3 P1 P2 Time Current ® Calibration point in time value 1 :29 81 :30 S1 32 Ss :25 Sp :25I Sp :27 ->S3 :27 P1 P2 P3 Time
BOPI
Sede Electrónica
